How Ritexitinib Performed in Clinical Trials

Ritlecitinib (Ritlecitinib) is a targeted therapy drug, a covalent AK3/TEC dual kinase inhibitor that is taken orally once daily. It has performed well in clinical trials and has brought new hope for the treatment of autoimmune diseases such as alopecia areata. In trials of patients with alopecia areata, ritexitinib significantly promoted hair regeneration and effectively reduced the area of u200bu200bbald areas. At the same time, the drug also performs well in terms of safety. Although there are some minor side effects, such as headache, diarrhea, etc., overall, it is well tolerated by patients. These positive clinical trial results provide strong support for further research and application of ritexitinib.